When epidermal growth factor (EGF) and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion.

Pathology

 cancer

Therapeutics

 over 25,000 women with breast cancer have now been treated with trastuzumab (Herceptin), a recombinant antibody designed to block the receptor ErbB2.
 small-molecule enzyme inhibitors
 monoclonal antibodies to ErbB1

References

 de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 2002;8(4 Suppl):S19-26. PMID: #11927283#

 Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37. PMID: #11252954#